WellSpan Health System York PA USA.
Department of Cardiovascular Medicine Cleveland Clinic Cleveland OH USA.
J Am Heart Assoc. 2024 Sep 3;13(17):e031461. doi: 10.1161/JAHA.123.031461. Epub 2024 Aug 27.
The treatment of severe aortic stenosis has evolved considerably since the introduction of transcatheter aortic valve replacement (TAVR), yet trends in complications for patients undergoing TAVR or surgical aortic valve replacement (SAVR) at a national level have yet to be evaluated.
We performed a retrospective cohort study using Medicare data to evaluate temporal trends in complications among beneficiaries, aged ≥65 years, treated with elective isolated transfemoral TAVR or SAVR between 2012 and 2019. The study end point was the occurrence of a major complication (composite outcome) during index and up to 30 days after. Multivariable logistic regression was used to assess odds of complications for TAVR and SAVR, individually over time, and for TAVR versus SAVR, over time. The cohort included 211 212 patients (mean±SD age, 78.6±7.3 years; 45.0% women). Complication rates during index following elective isolated aortic valve replacement decreased from 49% in 2012 to 22% in 2019. These reductions were more pronounced for TAVR (41% to >19%, Δ=22%) than SAVR (51% to >47%, Δ=4%). After risk adjustment, the risk of any complication with TAVR was 47% (<0.0001) lower compared with SAVR in 2012, and 78% (<0.0001) lower in 2019. TAVR was independently associated with reduced odds of complications each year compared with 2012, with the magnitude of benefit increasing over time (2013 versus 2012: odds ratio [OR], 0.89 [95% CI, 0.81-0.97]; 2019 versus 2012: OR, 0.35 [95% CI, 0.33-0.38]). These findings are consistent for complications up to 30 days from index.
Between 2012 and 2019, the risk of complications after aortic valve replacement among Medicare beneficiaries decreased significantly, with larger absolute and relative changes among patients treated with TAVR than SAVR.
自经导管主动脉瓣置换术(TAVR)问世以来,严重主动脉瓣狭窄的治疗已有了很大的发展,但在全国范围内,接受 TAVR 或外科主动脉瓣置换术(SAVR)的患者的并发症趋势尚未得到评估。
我们使用医疗保险数据进行了回顾性队列研究,以评估 2012 年至 2019 年期间,年龄≥65 岁的接受选择性经股动脉 TAVR 或 SAVR 治疗的受益人的并发症的时间趋势。研究终点是索引期间和索引后 30 天内发生主要并发症(复合结局)。多变量逻辑回归用于评估 TAVR 和 SAVR 各自随时间的并发症发生几率,以及 TAVR 与 SAVR 随时间的比较。该队列包括 211212 名患者(平均年龄±标准差,78.6±7.3 岁;45.0%为女性)。择期单纯主动脉瓣置换术后索引期间的并发症发生率从 2012 年的 49%下降到 2019 年的 22%。对于 TAVR(从 41%降至>19%,Δ=22%),这一降幅比 SAVR(从 51%降至>47%,Δ=4%)更为显著。在风险调整后,与 2012 年相比,TAVR 的任何并发症风险降低了 47%(<0.0001),2019 年降低了 78%(<0.0001)。与 2012 年相比,TAVR 每年发生并发症的几率都较低,且随着时间的推移,获益幅度逐渐增大(2013 年与 2012 年相比:比值比[OR],0.89[95%CI,0.81-0.97];2019 年与 2012 年相比:OR,0.35[95%CI,0.33-0.38])。这些发现与索引后 30 天内的并发症一致。
在 2012 年至 2019 年期间,医疗保险受益人的主动脉瓣置换术后并发症风险显著降低,TAVR 治疗患者的绝对和相对变化均大于 SAVR 治疗患者。